Ekso Bionics (NASDAQ:EKSO) Shares Cross Above 50 Day Moving Average – Should You Sell?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $10.16 and traded as high as $10.90. Ekso Bionics shares last traded at $10.15, with a volume of 44,832 shares.

Analyst Ratings Changes

Several equities research analysts have weighed in on EKSO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. Wall Street Zen raised Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. Finally, HC Wainwright lowered Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $6.00.

Ekso Bionics Price Performance

The firm has a market capitalization of $36.13 million, a PE ratio of -1.98 and a beta of 0.79. The business has a 50-day moving average of $10.16 and a 200 day moving average of $7.04. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 0.09.

Insiders Place Their Bets

In other news, major shareholder Daniel Asher acquired 15,540 shares of Ekso Bionics stock in a transaction on Thursday, February 19th. The stock was acquired at an average cost of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. This trade represents a 6.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Ekso Bionics

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Ekso Bionics during the third quarter valued at approximately $57,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at $67,000. Citadel Advisors LLC bought a new stake in shares of Ekso Bionics during the 3rd quarter worth $198,000. Geode Capital Management LLC boosted its holdings in shares of Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after buying an additional 10,281 shares during the last quarter. Finally, Consolidated Portfolio Review Corp bought a new position in Ekso Bionics during the third quarter valued at about $333,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.